Having trouble viewing this email? View in your browser.

1 June 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


ECCMID 2021 – Last chance to avoid the late fee

The regular registration fees for ECCMID 2021 are available until tomorrow, 2 June 2021. After this date, the late registration fees will apply.

Don’t miss out on the current prices for your full ECCMID registration, which also includes all of the Pre-ECCMID Days, as well as the ability to watch all of the great ECCMID content on-demand!

Complete your registration on the ESCMID website today!

› Read more

ESCMID Online Education Course: Clinical and social dimensions of the COVID-19 pandemic: the case of pregnant women and children

Don’t miss your chance to participate in the interactive online education course ‘Clinical and social dimensions of the COVID-19 pandemic: the case of pregnant women and children’, taking place from 11-12 June 2021.

The course is jointly organised by TAE, EVASG, Young ESPID, WATOG and IFMSA.

Check the exciting programme in the course flyer, and register on the ESCMID online courses website by June 7, 2021.

› Read more

ECCMID Slam Poetry Workshops - sign up today!

For ECCMID 2021, we are happy to be hosting 4 slam poetry workshops, one on each day of ECCMID, where participants can meet up in the company of a slam poet to express their life experiences during the COVID-19 Pandemic through the medium of slam poetry.

Slam poetry is an exciting artform that brings the classic expressiveness of poetry into a less-structured and more accessible package!

It could be about what has been happening in your hospital, at home or even online – whatever it is, we want to hear you slam about it!

A valid ECCMID registration is required in order to register for the workshop.

› Read more

EMA communication: "Human Medicines Highlights" Newsletter - May 2021

The latest edition of the EMA monthly Newsletter has been released, which includes decisions by their Scientific Committees and updates on medicines safety. 

You can access the Newsletter by clicking here. Previous editions can also be found on this page.

For more information on the European regulatory system for medicines, please click here (brochure available in all languages).

› Read more

Via BioMed Alliance: Implementation of the IVDR: a ticking time bomb for the diagnostic sector?

Laboratory experts from the BioMed Alliance IVD Working Group released a new statement highlighting a looming threat for the diagnostic sector: the slow implementation of the new In Vitro Diagnostic Regulation (IVDR). They argue that urgent actions are necessary now to prevent a collapse of the diagnostic sector.

The application date of the new In Vitro Diagnostics Regulation is only one year away (26 May 2022) and there are widespread concerns that the implementation is not progressing quickly enough and that the diagnostic sector is not ready. The new regulation proposes stricter safeguards for tests and additional elements in the regulatory framework for IVD tests, but so far, its implementation has been slow. As a result, not all elements and guidance are in place, making it harder for the diagnostic sector to prepare.

The BioMed Alliance, of which ESCMID is a member, has provided an overview of the implementation process and the steps to take and hopes that the issue will feature high on the EU agenda so pressing questions can be addressed.

› Read more

WHO CAESAR Annual Report 2020 available

The 2020 annual report of the WHO Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) network is now available.

The document is available on the WHO Regional office for Europe website.

ESCMID is proud to be a part of the WHO CAESAR Network.

› Read more

CMI highlight: Epidemiology, evolution and cryptic susceptibility of methicillin-resistant Staphylococcus aureus in China: a whole-genome-based survey

The aim of this study was to investigate the genomic epidemiology of Methicillin-resistant Staphylococcus aureus (MRSA) in China to identify predominant lineages and their associations with clinical data and antimicrobial resistance profiles. A national prevalence study of patients with S. aureus infections in 22 tertiary hospitals was performed in China from 2015 to 2017. Clinical data from patients and the antimicrobial phenotypes were collected for each isolate. Genome sequencing was performed on a proportion of isolates and a phylogenetic analysis undertaken. Genotypic and phenotypic β-lactam susceptibilities were compared. This study showed a high prevalence of CA-MRSA in China largely due to the widespread presence of CC59. As almost all isolates in this lineage possess genetic variants leading to increased β-lactam susceptibility, authors suggest that to improve antibiotic stewardship combinations of penicillins and β-lactamase inhibitors should be included in the antibiotic susceptibility testing panels used to inform treatment decisions and research undertaken on this combination therapy.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.